Mezagitamab Shows Promise in Treating Immune Thrombocytopenia Patients
Mezagitamab, an anti‑CD38 antibody originally developed for oncology, achieved a 91% platelet‑response rate in a phase 2 trial of patients with immune thrombocytopenia (ITP). In the 600 mg cohort, 10 of 11 participants reached the predefined platelet count threshold within 16 weeks, while the placebo group responded at only 23%. The drug raised platelet counts within 48 hours and displayed a safety profile similar to placebo. A phase 3 study is now enrolling in North America, with Mass General Brigham as the lead site.
America Has a New GLP-1 Playbook
The latest GLP‑1 oral formulations—Eli Lilly’s Foundayo and Novo Nordisk’s Wegovy pill—offer a needle‑free alternative but deliver modest weight‑loss results compared with their injectable counterparts. Clinical data show Foundayo can preserve most of the weight lost on injections over a year, while...
More Pharma Dealmaking; FDA’s Proposed Budget; Takeda Ends Partnership; and More
The pharma sector is seeing a wave of dealmaking, with Q1 2026 M&A volume up roughly 15% as companies chase high‑value oncology assets. The FDA released a proposed $5.6 billion budget that would raise review fees by about 8% and modestly...
Effects of Glucagon-Like Peptide-1 Receptor Agonists on Perioperative Outcomes in Hip and Knee Arthroplasty: A Systematic Review and Meta-Analysis
Researchers performed a systematic review and meta‑analysis of six retrospective cohort studies covering over 48,000 hip and knee arthroplasty patients to assess the impact of pre‑operative glucagon‑like‑peptide‑1 receptor agonist (GLP‑1 RA) therapy. The analysis found a 20 % reduction in revision...
Re: The Power of the Markets: The Scandal that Keeps on Taking
Lenacapavir, a once‑monthly injectable for HIV, is priced at $28,000 per patient annually by Gilead Sciences. In a BMJ rapid response, surgeon Simon Bell argued the price reflects the high cost of drug development and that Gilead is not obligated...
AI Can Screen 15 Million Molecules in a Day. It Still Can’t Cure Alzheimer’s.
Novartis used generative AI to design 15 million molecular‑glue candidates for Huntington’s disease and synthesized about 60, yielding a promising scaffold. While AI can trim early‑stage drug discovery timelines by 30‑40 percent and lower costs, no AI‑discovered compound has secured FDA approval...
New Yellow Fever Vaccine Matches Safety and Effectiveness of Current Shot
Sanofi's new live‑attenuated yellow fever vaccine, vYF, demonstrated safety and efficacy comparable to the licensed YF‑VAX in a phase 2 trial of 485 healthy adults. Protective antibodies appeared in 99.7% of vYF recipients versus 99.4% for YF‑VAX within 28 days, with...
EV-RNAs Show Promise for IBD Diagnosis and Treatment
A review in *ExRNA* led by Professor Xiyang Wei outlines how extracellular vesicle‑associated RNAs (EV‑RNAs) influence inflammatory bowel disease (IBD) pathogenesis and progression. By synthesizing multi‑omics and animal data, the authors show EV‑RNAs can serve as highly accurate, non‑invasive biomarkers...
Insilico Medicine Launches Pharma AI Spring Kickoff 2026 Webinar
Insilico Medicine announced the Pharma.AI Spring Kickoff 2026 webinar for April 14, 2026, at 10:00 AM ET. The event will showcase the company’s latest AI-driven drug discovery tools, including the MMAI Gym training framework, upgraded PandaOmics with single‑cell integration, and new capabilities in...
Big Pharma Is Turning to China for the Newest Drug Ideas
Pfizer is intensifying its search for breakthrough cancer treatments by tapping Chinese biotech. Last summer the company paid $1.25 billion to Shanghai‑based 3SBio for rights to a promising oncology candidate. The move reflects a broader shift as China evolves from a...
Nanomedicine Offers Targeted Solutions for Breast Cancer Treatment
Nanomedicine is reshaping breast cancer therapy by using nanoscale carriers to improve drug solubility, targeting, and controlled release. Recent preclinical studies show lipid‑polymer hybrids boosting oral bioavailability over threefold and photothermal nanoparticles halving tumor growth when combined with chemotherapy. Metallic...
Pyrazole-Derived TRPC3 Antagonist Ameliorates Synaptic Dysfunctions and Memory Deficits in Alzheimer’s Disease Models
Researchers have engineered a pyrazole‑derived, metabolically stable TRPC3 antagonist that readily penetrates the CNS. In cultured neurons, amyloid‑beta oligomers up‑regulate TRPC3, leading to calcium overload and toxicity. Administration of the compound to 5xFAD and APPKI mouse models reversed synaptic deficits...
Reprogramming Regulatory T Cells Could Help Immunotherapy Work in Pancreatic Cancer
Researchers at Oregon Health & Science University discovered that pancreatic tumors suppress immunotherapy by recruiting large numbers of regulatory T cells (Tregs). In mouse models, an agonistic CD40 therapy not only activated tumor‑killing immune cells but also reprogrammed Tregs into...
CMS Releases Proposed Rule Establishing Electronic Standards for Drug Prior Authorizations
The Centers for Medicare & Medicaid Services (CMS) issued a proposed rule on April 10 to create electronic standards for drug prior authorizations, extending the 2024 rule that standardized medical‑service prior authorizations. The proposal requires payers to accept API‑driven requests, shorten...
Finerenone Reduces Clinical Events in Patients With Heart Failure Regardless of CHD History
A prespecified analysis of the FINEARTS‑HF trial evaluated finerenone in 6,001 patients with heart‑failure with mildly reduced or preserved ejection fraction, 54% of whom had a history of coronary heart disease. Finerenone reduced the composite of cardiovascular death and heart‑failure...
Predictors of Rapid, Complete Skin Clearance With Psoriasis Biologics
A real‑world analysis of 299 moderate‑to‑severe psoriasis patients treated with biologics found that 76.3% achieved an early super‑response (PASI 100 by week 4 and maintained PASI < 1 through week 48). The strongest positive predictors were biologic‑naïve status and higher baseline neutrophil counts, while palmoplantar...
Real-World Evidence
The FDA is expanding its use of real‑world data (RWD) and real‑world evidence (RWE) to inform regulatory decisions beyond post‑market safety, including new drug indications and post‑approval study requirements. A 2018 framework, mandated by the 21st Century Cures Act, formalizes...
AI Analyzes Reddit Posts to Find Underreported GLP-1 Side Effects
Penn researchers used AI to scan over 400,000 Reddit posts from roughly 70,000 users, uncovering side‑effects of GLP‑1 drugs that are not fully captured in clinical trials. While gastrointestinal distress dominated, about 4% of users reported menstrual irregularities and a...
PreCheck Pilot Program Structure
The FDA’s PreCheck Pilot Program introduces a two‑phase pathway to speed the launch of new U.S. pharmaceutical manufacturing sites. Phase 1 delivers early, structured Pre‑Operational Reviews (POR) and builds a Type V Drug Master File that captures facility design, equipment qualification, and...
Oricell Therapeutics Secures $110 Million to Take on One of Oncology's Most Vexing Problems
Oricell Therapeutics closed a pre‑IPO financing round exceeding $110 million, led by Vivo Capital and a slate of international investors. The capital will fund global clinical expansion and further development of its proprietary CAR‑T platform targeting solid tumors. Oricell’s lead candidate,...
University of Cincinnati Launches Clinical Trial to Test New Drug for Prosthetic Joint Infections
The University of Cincinnati has begun enrolling patients in Peptilogics' RETAIN trial, a randomized, double‑blind study evaluating a novel peptide solution designed to penetrate biofilm in prosthetic joint infections (PJI). The trial will compare the peptide irrigant against a saline...
Cryo-EM Structural Biology Facility Opened in San Diego by FairJourney Bio
FairJourney Bio has launched an advanced cryo‑electron microscopy (cryo‑EM) structural biology facility in San Diego, featuring two 300 kV ThermoFisher Titan Krios 5 systems. The lab brings atomic‑resolution imaging directly into the company’s antibody discovery platform, supporting everything from epitope mapping to...
5 Vaccines Under Development That Would Change the World As We Know It
Recent advances in vaccine technology are targeting five of the world’s most persistent health threats: HIV, tuberculosis, cancer, influenza, and coronaviruses. Early-phase trials show mRNA‑based germline‑targeting approaches can induce broadly neutralizing antibodies against HIV, while the M72/AS01E candidate achieved roughly...
FDA Clears Investigational New Drug Application to Test sCAR-T Therapy for Autoimmune Conditions
The FDA has cleared Calibr‑Skaggs Institute’s investigational new drug application to test its switchable CAR‑T therapy, CLBR001 + SWI019, in a phase 1 trial for autoimmune diseases. The study will enroll patients with myositis, systemic sclerosis, lupus and rheumatoid arthritis, aiming to demonstrate...
Bioanalytical Method Validation for Biomarkers
The U.S. Food and Drug Administration issued final Level 2 guidance (Docket FDA‑2017‑D‑6821) on bioanalytical method validation for biomarkers. It outlines the evidentiary standards for measuring biomarker concentrations in clinical trials and non‑clinical studies. The guidance applies to IND, NDA, BLA, ANDA,...
Alpheus Medical Advances to Phase 2b Testing of Experimental Brain Cancer Therapy
Alpheus Medical has enrolled 10 patients in a Phase 2b randomized trial of its Porphyrin Metabolite Activation (PoMA) therapy for newly diagnosed glioblastoma. PoMA uses a tumor‑selective drug activated by low‑intensity diffuse ultrasound to treat the entire affected brain hemisphere,...
Bayer Pharma Executive Predicts US-Europe Price Spreads Will Narrow
Bayer's chief operating officer for pharmaceuticals warned that the long‑standing price gap between the United States and European markets will shrink sharply. He attributes the change to the Trump administration's push for “most‑favored‑nation” (MFN) pricing agreements, which compel manufacturers to...
Replimune’s Advanced Melanoma Drug Rebuffed by FDA for Second Time
Replimune’s oncolytic immunotherapy RP1, aimed at unresectable advanced cutaneous melanoma, was rejected by the FDA for a second time on April 6, 2026. The agency’s complete response letter said the data, derived from a single‑arm trial, were insufficient to demonstrate substantial effectiveness,...
BMS and Oxford BioTherapeutics Join Forces in TCE Discovery Pact
Bristol Myers Squibb has entered a discovery partnership with Oxford BioTherapeutics to develop T‑cell engager (TCE) therapies for solid tumours. BMS will pay an undisclosed upfront fee to access OBT’s OGAP‑Verify platform, while OBT will design and deliver pre‑clinical candidates....
Drugs From a Text Prompt, Wegovy Pill Competition Dampens Lilly’s Surge
Agentic AI is revolutionizing drug discovery, allowing scientists to generate candidates from simple text prompts and run extended‑reality guided experiments. In parallel, Gilead announced a deal to acquire Tubulis for up to $5 billion, strengthening its antibody‑drug conjugate portfolio. Eli Lilly and...
Other News to Note for April 10, 2026
BioWorld’s April 10 briefing highlights three notable developments. Jiangsu and Shanghai Hengrui have patented novel Nav1.8 sodium‑channel blockers, a class of compounds with potential for pain and inflammatory disease therapies. New hematopoietic stem‑cell research links chronic inflammation to early‑stage leukemia, deepening...
China Biotech’s CRISPR Therapy Suggests US Drugmakers Will Face Competition
A Chinese biotech firm used CRISPR‑Cas9 to edit blood stem cells in five beta thalassemia patients, eliminating their need for regular transfusions. The ex‑vivo therapy reactivates fetal hemoglobin and showed durable engraftment with no serious adverse events over a year...
Using Menstrual Blood-Derived Particles to Treat Osteoarthritis
Lithuanian researchers have demonstrated that extracellular vesicles (EVs) harvested from menstrual‑blood‑derived mesenchymal stromal cells can stimulate cartilage regeneration in vitro, offering a cell‑free therapy for osteoarthritis. The EVs improved chondrocyte function and extracellular matrix synthesis even in cartilage cells taken...
Oricell Closes a ‘Pre-IPO’ Megaround to Aim CAR-T at Solid Tumors
Oricell Therapeutics, a Shanghai‑based biotech, closed a pre‑IPO financing round of more than $110 million to accelerate its CAR‑T programs targeting solid tumors, starting with liver cancer. Its lead candidate, Ori‑C101, targets the GPC3 protein and has shown a 60% response...
Vivatides Gets $54M; Wegovy Drops Cold Chain in EU; Gilead Takes Kymera Option
Vivatides Therapeutics announced a $54 million Series A round to accelerate its pre‑clinical siRNA and antisense oligonucleotide programs, with Sequoia Capital leading the investment. In Europe, Novo Nordisk confirmed that its obesity drug Wegovy will drop the costly cold‑chain requirement, simplifying distribution. Meanwhile,...
PDUFA and BsUFA Quarterly Hiring Updates
The FDA published its quarterly hiring updates for fiscal years 2023‑2027 under PDUFA VII and BsUFA III. FY2023 staffing was almost complete—CBER filled 99% of its 132 positions and CDER 90% of 77—while FY24 reached only 71% of 79 targeted FTEs. FY25...
FDA/Center for Research on Complex Generics (CRCG) Workshop on Bioequivalence Innovations for Generic Oral Products: Biowaivers, Bridging, and Development for...
On May 5‑6, 2026, the FDA’s Center for Research on Complex Generics hosted a two‑day workshop in Rockville, MD to explore innovative bioequivalence (BE) strategies for generic oral drugs. The agenda covered biowaivers, bridging studies, and development pathways for oncology agents,...
Biotech VCs Ramp up Checks on New Bets After Years of Focusing on Existing Portfolios
Biotech venture capitalists are shifting back to high‑risk, high‑reward investing, with 65% of Q1 2026 capital directed at new startups. Total venture funding in the sector rose to roughly $2.1 billion, up from $1.5 billion a quarter earlier, and average deal size climbed...
An Implantable Living Pharmacy Produces Drugs in the Body
Scientists from Northwestern, Rice, and Carnegie Mellon unveiled a sub‑cutaneous implant called HOBIT that can synthesize multiple biologic drugs inside the body. The device houses engineered cells in an alginate hydrogel and an electrocatalytic oxygenator that supplies oxygen, enabling sustained...
What’s in a Name? Moderna’s “Vaccine” Vs. “Therapy” Dilemma
Moderna has stopped calling its mRNA melanoma product a "vaccine," rebranding it as an individualized neoantigen therapy (INT) to sidestep growing political resistance to vaccines. The shift follows the cancellation of a $776 million federal bird‑flu vaccine contract and broader skepticism...
Vutrisiran Cuts Risk of Advanced ATTR-CM, Improves Outcomes in Those Who Progress
Vutrisiran (Amvuttra) demonstrated in the phase 3 HELIOS‑B trial that it slows progression to advanced heart failure in transthyretin amyloid cardiomyopathy (ATTR‑CM), with 8.0% of treated patients reaching advanced disease versus 10.7% on placebo. Among the 61 patients who did progress,...
Emerging Therapies Bring Hope for Frail HNSCC Patients Unfit for Standard Treatment
Head and neck squamous cell carcinoma (HNSCC) cases are projected to rise to 273,000 by 2034, with frail and elderly patients expected to comprise 44% of the market. Standard curative regimens are often intolerable for this group, creating a sizable...
Revvity Unveils Its Signals BioDesign Offering
Revvity Signals Software introduced Signals BioDesign, a cloud‑native molecular cloning platform aimed at biotech and pharma R&D teams. The solution consolidates Golden Gate, Gibson assembly, restriction/ligation, primer design, and sequencing analysis, supporting up to 1,000 constructs per project. Integrated with...
Top Biotech Deals in March 2026
Biotech M&A activity peaked in March 2026 with twelve announced deals, eight of which were multi‑billion‑dollar transactions. The largest was Lilly’s $7.8 billion acquisition of Centessa, adding an orexin‑receptor‑2 program for narcolepsy. Other marquee deals included Biogen’s $5.6 billion purchase of Apellis, Merck’s...
Senju Launches First-in-Class Dry Eye Disease Drug in Japan
Senju Pharma has launched Avarept, the first TRPV1 antagonist drug for dry eye disease (DED) in Japan, licensed from Mochida and distributed by Takeda. The ophthalmic suspension is priced at ¥577.50 (approximately $3.63) per 5 ml bottle. DED affects over 20 million...
Pharmaceutical Tariffs and the Restructuring of Global Drug Supply Chains
The United States is rolling out new tariffs on imported pharmaceutical products, affecting an estimated $200‑$250 billion in annual trade. Because 70‑80% of active pharmaceutical ingredient (API) production is concentrated in India and China, manufacturers face limited flexibility and longer lead...
Oxford BioTherapeutics Partners with BMS to Develop Next-Generation T-Cell Engagers for Solid Tumors
Oxford BioTherapeutics (OBT) announced a multi‑year strategic collaboration with Bristol Myers Squibb (BMS) to discover and develop next‑generation T‑cell engager therapies for solid tumors. OBT will apply its OGAP‑Verify platform to identify tumor‑selective antigens and design candidate molecules, while BMS...
Oricell Therapeutics Raises $110 Million to Advance Global Cell Therapy Development
Oricell Therapeutics announced a $110 million pre‑IPO financing round aimed at accelerating its global cell‑therapy program. The capital will fund expanded clinical trials, manufacturing upgrades, and a broader market rollout, especially for its lead liver‑cancer therapy that is nearing pivotal studies....
Will RFK Jr.’s Peptide Push Bolster the Gray Market for Obesity Drugs?
Robert F. Kennedy Jr. is urging the FDA to reclassify more than a dozen synthetic peptides from the restricted Category 2 list to Category 1, allowing compounding by licensed pharmacies with a prescription. The move follows a high‑profile appearance on the Joe...
Biotech’s IPO Comeback; Trump’s Tariff Loophole for Pharma
Biotech IPO activity is resurging, highlighted by Evommune’s public listing and a panel at the BIO International Convention discussing renewed exit opportunities. AI-driven collaborations, such as Insilico Medicine and Aska Pharmaceutical, aim to tackle unmet needs in women’s health by...